Psoriasis therapy - Apollo Life Sciences

Drug Profile

Psoriasis therapy - Apollo Life Sciences

Alternative Names: ALS-00T2-0501; Transdermal TNF blocker for psoriasis - Apollo Life Sciences

Latest Information Update: 09 Mar 2011

Price : $50

At a glance

  • Originator Apollo Life Sciences
  • Class
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 23 Jan 2006 Apollo Life Sciences has completed treatment in a phase Ib trial for Psorasis in Australia
  • 18 Oct 2005 Phase-I clinical trials in Psoriasis in Australia (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top